0
0
A new study presented at the European Psychiatric Association Congress 2024 has unveiled a concerning correlation between depression and mortality risk among women battling breast cancer, the most prevalent cancer among females worldwide.
Researchers from Russia conducted an extensive analysis of studies spanning from 1977 to 2018, investigating the impact of depression on survival rates and quality of life in women diagnosed with breast cancer.
The findings, revealed at the congress held in Hungary, shed light on the varying prevalence of depression among breast cancer patients, ranging from 4.5% to 38% across different studies.
Of significant concern is the observed spike in mortality rates among patients with early-stage breast cancer (stage I & II) who also battle depression. The study identified a staggering 2-2.5-fold increase in breast cancer-specific and all-cause mortality in this population.
Moreover, women with non-metastatic breast cancer faced a 2.5 times greater risk of death within 8-15 years if they also struggled with depression.
The research underscores the detrimental impact of both depression and anxiety on survival rates and overall quality of life for breast cancer patients.
Professor Ilgiz G. Gataullin from the Department of Oncology, Radiology, and Palliative Medicine at the Kazan State Medical Academy in Russia emphasized the critical need for improved screening methods for mental health conditions in breast cancer patients. While psychotherapy and antidepressant treatments may offer potential avenues for reducing psychological distress, further research is imperative in this domain.
The study’s findings highlight the urgent need for comprehensive support and mental health interventions tailored to the unique needs of breast cancer patients. By addressing the mental health aspect alongside medical treatment, healthcare providers can potentially improve outcomes and enhance the overall well-being of individuals navigating the complexities of breast cancer diagnosis and treatment.
